Polyphor to present at the H.C. Wainwright Global Investment Conference Mittwoch, 04. September 2019 - 17:39

Polyphor AG / Key word(s): Conference Polyphor to present at the H.C. Wainwright Global Investment Conference

04.09.2019 / 17:38

---------------------------------------------------------------------------

Allschwil, Switzerland, September 4, 2019

Polyphor to present at the H.C. Wainwright Global Investment Conference

Polyphor AG (SIX: POLN) today announced that the company will present at the 21st Annual H.C. Wainwright Global Investment Conference, taking place September 8-10, 2019 in New York City. Giacomo Di Nepi, CEO of Polyphor, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. A live webcast of the presentation will be accessible on Polyphor's website on the Investor Relations page on the Calendar tab or under the following link: Polyphor Webcast. A replay of the webcast will be available for 90 days following the conclusion of the event.

Presentation details: Date: September 9, 2019 Time: 03:25 - 03:50pm EDT Location: The Lotte Palace Hotel, New York Webcast: Polyphor Webcast

For further information please contact:

For Investors: Kalina Scott Chief Financial Officer Polyphor Ltd. Tel: +41 61 567 16 67 Email: IR@polyphor.com

For Media: Alexandre Müller Dynamics Group AG Tel: +41 43 268 32 31 Email: amu@dynamicsgroup.ch

About Polyphor Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer, and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.